South Korean pharmaceutical and medical aesthetics companies are advancing across obesity therapeutics, toxin branding, device exhibitions, and tissue-based CDMO. Hanmi Pharmaceutical unveiled preclinical obesity drug data at the American Diabetes Association conference, while Inibio prepares to showcase its botulinum toxin brand 'Inibo' at AMWC Korea 2026. HuonsMeditech exhibited its dermal injection devices in Indonesia, and CGBio signed a CDMO deal with Kolon Pharma for human ECM-based skin booster products. Dong-A Pharmaceutical is running a consumer pop-up for its energy drink Bacchus in Seoul.
Obesity drug pipeline signals
Hanmi Pharmaceutical presented eight research findings on obesity candidates HM17321 and HM500197 at the American Diabetes Association annual meeting in New Orleans earlier this month. For HM500197, animal studies showed that combining it with a GLP-1 receptor agonist suppressed muscle loss, suggesting potential for healthier weight reduction. HM17321 demonstrated possible benefits in muscle gain and bone health improvement. These developments are relevant for aesthetic and metabolic device or injectable buyers tracking next-generation body-contouring and weight-management adjuncts.
Aesthetic device and needle showcase in Indonesia
HuonsMeditech, part of Huons Group, participated in the AMUSE 2026 beauty conference exhibition in Jakarta from June 12-14. The company featured its drug-dose injector 'DermaShine Duo RF' and the 'Premium 9-Pin Needle' for skin booster applications. For overseas distributors and clinics, this signals Huons' continued push into the Southeast Asian aesthetic device market with precision injection tools.
Botulinum toxin brand launch at AMWC Korea 2026
Inibio will attend AMWC Korea 2026 as a diamond sponsor on June 19-20 at the Grand InterContinental Seoul Parnas. The company plans to introduce its botulinum toxin brand 'Inibo' through a booth and symposium titled 'Clinical Diversification of Inibo,' featuring various clinical cases. This is a key opportunity for buyers evaluating new toxin entrants in the Korean and regional aesthetic injectable market.
Human ECM-based CDMO deal for skin boosters
CGBio (formerly Sijimedtech) announced a CDMO contract with Kolon Pharma for human extracellular matrix (hECM)-based tissue products intended for skin booster use. hECM is a human-derived mesh-like structure that supports tissue regeneration. This partnership is relevant for aesthetic clinics and distributors seeking OEM/ODM sources for regenerative dermal filler or booster products.
What buyers should watch
Hanmi's obesity candidates could eventually complement aesthetic body-contouring portfolios. Inibio's toxin launch at AMWC Korea provides a direct channel for distributors to evaluate a new botulinum toxin brand. Huons' device showcase in Indonesia indicates growing regional demand for precision injectors. CGBio's CDMO deal with Kolon Pharma highlights the trend toward human-derived biomaterials in skin boosters. Dong-A's Bacchus pop-up is a consumer marketing move with no direct aesthetic supply-chain impact.
Source: Read the original report | Published: June 16, 2026